James Healy - 05 Aug 2022 Form 4 Insider Report for CinCor Pharma, Inc.

Signature
/s/ Cathy Rude, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
05 Aug 2022
Net transactions value
+$399,990
Form type
4
Filing time
08 Aug 2022, 12:57:35 UTC
Previous filing
19 Jul 2022
Next filing
15 Aug 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CINC Common Stock Options Exercise $399,990 +29,411 $13.60 29,411 05 Aug 2022 Direct F1
holding CINC Common Stock 5,573,949 05 Aug 2022 By Sofinnova Venture Partners X, L.P. F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CINC Stock Option (Right to Buy) Options Exercise $0 -29,411 -100% $0.000000* 0 05 Aug 2022 Common Stock 29,411 $13.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 29,411 shares were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Issuer, which shall lapse with respect to one-third of the shares on December 10, 2022 and with respect to one-third of the shares each year thereafter, subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.
F2 The shares are directly held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X") is the general partner of SVP X. The Reporting Person is a managing member of SM X and may be deemed to share voting and dispositive power over the shares held by SVP X. The Reporting Person disclaims beneficial ownership of the reported securities, except to the extent of his pecuniary interest therein.
F3 This option vests in equal annual installments over a three-year period measured from one year following December 10, 2021, subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date.